Management of dyslipidemia in diabetes

Maria Solano, Ronald B Goldberg

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Diabetes is associated with a high risk of cardiovascular disease. The management of dyslipidemia, a well-recognized and modifiable risk factor among patients with type 2 diabetes, is an important element in the multifactorial approach to prevent coronary heart disease. Diabetic dyslipidemia typically consists of elevated triglyceride, low high-density lipoprotein cholesterol (HDL-C), and the predominance of small dense low-density lipoprotein (LDL) particles. LDL cholesterol (LDL-C) levels in patients with diabetes are similar to those found in the rest of the population. During the past few years, clinical trials have provided evidence that lipid-lowering therapy has a similar beneficial effect on cardiovascular outcomes in diabetic and nondiabetic individuals. According to current guidelines, the primary lipid target is an LDL-C <100 mg/dL (<70 mg/dL in very high-risk patients) and, to this end, statins are the agents of choice. The appropriate management of dyslipidemia in patients with diabetes, particularly in individuals with low LDL-C, remains controversial. To achieve lipid targets, attention should be directed first toward nonpharmacologic therapeutic interventions to control dyslipidemia, such as diet, exercise, smoking cessation, weight loss, and glycemic control. Statin therapy is recommended for most subjects but, frequently, a combination of lipid-lowering agents is required. A number of combinations are possible, and several factors should be considered to improve the safety of this strategy.

Original languageEnglish
Pages (from-to)125-135
Number of pages11
JournalCardiology in Review
Volume14
Issue number3
DOIs
StatePublished - May 1 2006

Fingerprint

Dyslipidemias
LDL Lipoproteins
Lipids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
LDL Cholesterol
Smoking Cessation
Type 2 Diabetes Mellitus
HDL Cholesterol
Coronary Disease
Weight Loss
Triglycerides
Cardiovascular Diseases
Therapeutics
Clinical Trials
Guidelines
Exercise
Diet
Safety
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Management of dyslipidemia in diabetes. / Solano, Maria; Goldberg, Ronald B.

In: Cardiology in Review, Vol. 14, No. 3, 01.05.2006, p. 125-135.

Research output: Contribution to journalArticle

Solano, Maria ; Goldberg, Ronald B. / Management of dyslipidemia in diabetes. In: Cardiology in Review. 2006 ; Vol. 14, No. 3. pp. 125-135.
@article{5d9ae5063c4149b191435967fc8f2e82,
title = "Management of dyslipidemia in diabetes",
abstract = "Diabetes is associated with a high risk of cardiovascular disease. The management of dyslipidemia, a well-recognized and modifiable risk factor among patients with type 2 diabetes, is an important element in the multifactorial approach to prevent coronary heart disease. Diabetic dyslipidemia typically consists of elevated triglyceride, low high-density lipoprotein cholesterol (HDL-C), and the predominance of small dense low-density lipoprotein (LDL) particles. LDL cholesterol (LDL-C) levels in patients with diabetes are similar to those found in the rest of the population. During the past few years, clinical trials have provided evidence that lipid-lowering therapy has a similar beneficial effect on cardiovascular outcomes in diabetic and nondiabetic individuals. According to current guidelines, the primary lipid target is an LDL-C <100 mg/dL (<70 mg/dL in very high-risk patients) and, to this end, statins are the agents of choice. The appropriate management of dyslipidemia in patients with diabetes, particularly in individuals with low LDL-C, remains controversial. To achieve lipid targets, attention should be directed first toward nonpharmacologic therapeutic interventions to control dyslipidemia, such as diet, exercise, smoking cessation, weight loss, and glycemic control. Statin therapy is recommended for most subjects but, frequently, a combination of lipid-lowering agents is required. A number of combinations are possible, and several factors should be considered to improve the safety of this strategy.",
author = "Maria Solano and Goldberg, {Ronald B}",
year = "2006",
month = "5",
day = "1",
doi = "10.1097/01.crd.0000188034.76283.5e",
language = "English",
volume = "14",
pages = "125--135",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Management of dyslipidemia in diabetes

AU - Solano, Maria

AU - Goldberg, Ronald B

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Diabetes is associated with a high risk of cardiovascular disease. The management of dyslipidemia, a well-recognized and modifiable risk factor among patients with type 2 diabetes, is an important element in the multifactorial approach to prevent coronary heart disease. Diabetic dyslipidemia typically consists of elevated triglyceride, low high-density lipoprotein cholesterol (HDL-C), and the predominance of small dense low-density lipoprotein (LDL) particles. LDL cholesterol (LDL-C) levels in patients with diabetes are similar to those found in the rest of the population. During the past few years, clinical trials have provided evidence that lipid-lowering therapy has a similar beneficial effect on cardiovascular outcomes in diabetic and nondiabetic individuals. According to current guidelines, the primary lipid target is an LDL-C <100 mg/dL (<70 mg/dL in very high-risk patients) and, to this end, statins are the agents of choice. The appropriate management of dyslipidemia in patients with diabetes, particularly in individuals with low LDL-C, remains controversial. To achieve lipid targets, attention should be directed first toward nonpharmacologic therapeutic interventions to control dyslipidemia, such as diet, exercise, smoking cessation, weight loss, and glycemic control. Statin therapy is recommended for most subjects but, frequently, a combination of lipid-lowering agents is required. A number of combinations are possible, and several factors should be considered to improve the safety of this strategy.

AB - Diabetes is associated with a high risk of cardiovascular disease. The management of dyslipidemia, a well-recognized and modifiable risk factor among patients with type 2 diabetes, is an important element in the multifactorial approach to prevent coronary heart disease. Diabetic dyslipidemia typically consists of elevated triglyceride, low high-density lipoprotein cholesterol (HDL-C), and the predominance of small dense low-density lipoprotein (LDL) particles. LDL cholesterol (LDL-C) levels in patients with diabetes are similar to those found in the rest of the population. During the past few years, clinical trials have provided evidence that lipid-lowering therapy has a similar beneficial effect on cardiovascular outcomes in diabetic and nondiabetic individuals. According to current guidelines, the primary lipid target is an LDL-C <100 mg/dL (<70 mg/dL in very high-risk patients) and, to this end, statins are the agents of choice. The appropriate management of dyslipidemia in patients with diabetes, particularly in individuals with low LDL-C, remains controversial. To achieve lipid targets, attention should be directed first toward nonpharmacologic therapeutic interventions to control dyslipidemia, such as diet, exercise, smoking cessation, weight loss, and glycemic control. Statin therapy is recommended for most subjects but, frequently, a combination of lipid-lowering agents is required. A number of combinations are possible, and several factors should be considered to improve the safety of this strategy.

UR - http://www.scopus.com/inward/record.url?scp=33748444602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748444602&partnerID=8YFLogxK

U2 - 10.1097/01.crd.0000188034.76283.5e

DO - 10.1097/01.crd.0000188034.76283.5e

M3 - Article

C2 - 16628021

AN - SCOPUS:33748444602

VL - 14

SP - 125

EP - 135

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 3

ER -